Cynata Therapeutics


Company Announcements:
(reported by the Company)
Elevator Pitch:

Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison (UWM). UWM is a world-renowned leader in stem cell research, in particular for the work by Professor James Thomson's group, which included the first successful isolation of human embryonic stem cells in 1998, and the derivation of induced pluripotent stem cells (iPSCs) from human adult cells in 2007. Professor Igor Slukvin, a co-founder of Cynata, was also a member of the team that conducted UWM's pioneering iPSC research.

Cynata's Cymerus™ platform stem cell technology is based upon extremely important and versatile stem cells known as mesenchymoangioblasts (MCAs). MCAs are a precursor of mesenchymal stem (or stromal) cells (MSCs) which are at the forefront of a new generation of treatments being investigated for such devastating diseases as osteoarthritis, Crohn’s disease and heart disease. Cynata’s proprietary technology utilizes iPSCs originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product.

Category: Health & biotech
Operational Status: Active
ASX Listing Code (if applicable): CYP
Year of Commencement:

Registered Office Address:

Suite 1,
1233 High Street,
Armadale, Victoria 3143

State: Victoria, Western Australia
Overseas Operations: No
Key Personnel:
Awards won:
Current Period Rank:

Annual Rank (top 100 ranked companies only): 73

WA Annual Rank 2016: 16


    September, 2017

    In principle agreement from Health Canada that the Cymerus process meets its expectations for a product entering clinical trials

    Granted a patent for Cymerus mesenchymal stem cell technology in the US

    July, 2017

    Successfully completed pre-IND meeting with the US's FDA

    January, 2017

    Completed a placement to sophisticated and institutional investors to raise $6 million

    December, 2016

    Received approval from the NHS in England for the Phase 1 trial in patients with steroid-resistant acute GvHD


Company News:

NOTE: Company News, Milestones and Funding are as collected by Techboard as part of our Monthly Startup Ranking

Amount Seeking:
Type of capital raise:
Pre-money valuation:
ESIC Status:
ESIC Upload:
Future Intentions:
Investment Video:
Investment Pitchdeck:
Investment URL:
Investment Phone:
Investment Email:


Anne Dunne, Monsoon communications

Leave a Reply